Product and Pipeline

Introduction to Clinical-Grade Human CiPS Cell Lines

BeiCell Therapeutics has established a comprehensive production process for clinical-grade human CiPS cell lines, ensuring that each step adheres to rigorous scientific standards and operational protocols. This process includes initial screening of healthy donors, collection and transportation of adipose tissue, isolation and culture of somatic cells, chemical reprogramming to generate human CiPS cells, and expansion and stringent quality control of the cell lines. To date, BeiCell Therapeutics has successfully collected adipose tissue from three healthy donors and produced multiple high-quality human CiPS cell lines in a GMP-compliant facility. These cell lines not only meet the urgent demands of current cell therapy product development but also provide strong support for the future development of innovative therapies.

Advantages of Clinical-Grade Human CiPS Cells

· Pluripotency: Human CiPS cells possess pluripotency, enabling them to differentiate into various types of functional cells.

· Safety: Compared to traditional somatic cell reprogramming techniques, chemical reprogramming avoids the use of oocytes and exogenous genes, reducing ethical concerns and the risk of genetic mutations.

· Efficiency: Reprogramming somatic cells using only small molecules is straightforward and highly efficient.

· Stability: Clinical-grade human CiPS cell lines are subject to rigorous quality control and screening, ensuring high consistency in genetic stability and biological characteristics.

Clinical-Grade Human CiPS Cell Line Information

If you have a need for clinical-grade human CiPS cell lines, please contact us at:

Ms. Wang, Tel: +86 13716368939, Email: xiaoqing.wang@beicelltherapeutics.com